Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

[1]  Stefan Blankenberg,et al.  High-sensitivity assays for troponin in patients with cardiac disease , 2017, Nature Reviews Cardiology.

[2]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[3]  D. Newby,et al.  High-Sensitivity Troponin I Is Associated With High-Risk Plaque and MACE in Stable Coronary Artery Disease. , 2017, JACC. Cardiovascular imaging.

[4]  H. Katus,et al.  Prognostic value of elevated high-sensitivity cardiac troponin T levels in a low risk outpatient population with cardiovascular disease , 2016, European heart journal. Acute cardiovascular care.

[5]  Mark R Segal,et al.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. , 2016, JAMA.

[6]  Kim Ekroos,et al.  Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol , 2016, European heart journal.

[7]  A. Philippakis,et al.  Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape , 2015, Journal of the American Heart Association.

[8]  Deepak L. Bhatt,et al.  Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.

[9]  E. Vittinghoff,et al.  Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study , 2015, Journal of the American Heart Association.

[10]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[11]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[12]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[13]  G. Collins,et al.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement , 2015, British Journal of Cancer.

[14]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[15]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[16]  W. März,et al.  Evolving biomarkers improve prediction of long‐term mortality in patients with stable coronary artery disease: the BIO‐VILCAD score , 2014, Journal of internal medicine.

[17]  J. Goetze,et al.  Natriuretic peptides in cardiometabolic regulation and disease , 2014, Nature Reviews Cardiology.

[18]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[19]  H. Schunkert,et al.  Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. , 2014, Cardiovascular revascularization medicine : including molecular interventions.

[20]  Spiros Denaxas,et al.  Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients , 2013, European heart journal.

[21]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[22]  W. März,et al.  High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study , 2013, Clinical chemistry and laboratory medicine.

[23]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[24]  W. März,et al.  Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. , 2012, European heart journal.

[25]  Deepak L. Bhatt,et al.  An international model to predict recurrent cardiovascular disease. , 2012, The American journal of medicine.

[26]  H. White.  Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? , 2011, Journal of the American College of Cardiology.

[27]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[28]  K. Nakao,et al.  Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. , 2011, Journal of cardiology.

[29]  M. Durand,et al.  Salzburg statement on shared decision making , 2011, BMJ : British Medical Journal.

[30]  A. Khera,et al.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.

[31]  C. Held,et al.  Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. , 2010, American heart journal.

[32]  E. Benjamin,et al.  Multiple marker approach to risk stratification in patients with stable coronary artery disease. , 2010, European heart journal.

[33]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[34]  S. Solomon,et al.  Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[35]  D. Atsma,et al.  Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation , 2007, Pflügers Archiv - European Journal of Physiology.

[36]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[37]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[38]  K. Bibbins-Domingo,et al.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.

[39]  D. Tanné,et al.  Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. , 2006, The American journal of cardiology.

[40]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[41]  R. Schnabel,et al.  Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. , 2005, European heart journal.

[42]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[43]  I. Marschner,et al.  Long-term risk stratification for survivors of acute coronary syndromes - Results from the long-term intervention with pravastatin in ischemic disease (LIPID) study , 2001 .

[44]  J. Canty,et al.  Preload Induces Troponin I Degradation Independently of Myocardial Ischemia , 2001, Circulation.

[45]  W. März,et al.  Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.

[46]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[47]  U. Dohrmann,et al.  Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium: Influence of Angiotensin II and Diastolic Fiber Length , 2000, Circulation.

[48]  F. Apple,et al.  Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[49]  B. Bruneau,et al.  BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. , 1997, The American journal of physiology.